Press release
Friedreich's Ataxia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Friedreich's Ataxia Treatment Landscape. Click here to read more @ Friedreich's Ataxia Pipeline Outlook [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Friedreich's Ataxia Pipeline Report
* In April 2025, Reata announced a study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of participants with Friedreich's ataxia.
* In April 2025, PTC Therapeutics conducted a study will serve as a continued access study for participants with FA who have previously participated in a vatiquinone study. The purpose of this study is to assess continued safety and efficacy of vatiquinone dosing in previously treated participants. This study addresses the medical need for participants to continue vatiquinone with a planned study duration of 3 years.
* DelveInsight's Friedreich's Ataxia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Friedreich's Ataxia treatment.
* The leading Friedreich's Ataxia Companies such as PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
* Promising Friedreich's Ataxia Pipeline Therapies such as Vatiquinone, Interferon Gamma-1b, MIB-626, Elamipretide, CTI-1601, MIN-102, TAK-831, EPI-743 and others.
Stay informed about the cutting-edge advancements in Friedreich's Ataxia Treatments. Download for updates and be a part of the revolution in Neurology care @ Friedreich's Ataxia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Friedreich's Ataxia Emerging Drugs
* RT 001: Retrotope
RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope's novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It is currently in phase III stage of development for Friedreich's ataxia and is being developed by Retrotope.
* Leriglitazone: Minoryx Therapeutics
Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination and axonal degeneration. It is currently in phase II stage of development and is being developed by Minoryx Therapeutics.
Friedreich's Ataxia Market Drivers
* Rapid research in the field of ataxia therapeutics
* Increasing collaborations and acquisitions among key players
Friedreich's Ataxia Market Barriers
* There are currently no approved therapies for the treatment of patients with Friedreich's ataxia.
Get a detailed analysis of the latest innovations in the Friedreich's Ataxia pipeline. Explore DelveInsight's expert-driven report today! @ Friedreich's Ataxia Unmet Needs [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Friedreich's Ataxia pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Friedreich's Ataxia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Friedreich's Ataxia Treatment.
* Friedreich's Ataxia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Friedreich's Ataxia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Friedreich's Ataxia market.
Friedreich's Ataxia Companies
PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
Friedreich's Ataxiapipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Friedreich's Ataxia Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
Discover the latest advancements in Friedreich's Ataxia Treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Friedreich's Ataxia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Friedreich's Ataxia Pipeline Report
* Coverage- Global
* Friedreich's Ataxia Companies- PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
* Friedreich's Ataxia Pipeline Therapies- Vatiquinone, Interferon Gamma-1b, MIB-626, Elamipretide, CTI-1601, MIN-102, TAK-831, EPI-743 and others.
* Friedreich's Ataxia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Friedreich's Ataxia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Friedreich's Ataxia Pipeline on our website @ Friedreich's Ataxia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Friedreich's Ataxia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Friedreich's Ataxia- DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Friedreich's Ataxia Collaboration Deals
* Late Stage Products (Phase III)
* RT 001: Retrotope
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Leriglitazone: Minoryx Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CTI-1601: Larimar Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* LX-2006: LEXEO Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Friedreich's Ataxia Key Companies
* Friedreich's Ataxia Key Products
* Friedreich's Ataxia- Unmet Needs
* Friedreich's Ataxia- Market Drivers and Barriers
* Friedreich's Ataxia- Future Perspectives and Conclusion
* Friedreich's Ataxia Analyst Views
* Friedreich's Ataxia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=friedreichs-ataxia-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/friedreichs-ataxia-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Friedreich's Ataxia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3991336 • Views: …
More Releases from ABNewswire
Niemann Pick C Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approval …
DelveInsight's "Niemann Pick C Disease Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann Pick C Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive…
Microencapsulation Market Overview, Latest Trends, Growth Drivers, Key Segments, …
Microencapsulation Market by Shell Material (Polymers, Gums & Resins, Lipids, Carbohydrates, Proteins), Technology, Core Material, Core Material Form, End-Use Industry, Functionality, and Region - Global Forecast to 2029
The microencapsulation market [https://www.prnewswire.com/news-releases/microencapsulation-market-worth-24-07-billion-by-2029--exclusive-report-by-marketsandmarkets-302287110.html] is valued at USD 15.38 billion in 2024 and is expected to reach USD 24.07 billion by 2029, growing at a CAGR of 9.4% during the forecast period. This growth is driven by microencapsulation's critical role in enhancing product…
Risk Analytics Market To Reach $51.34 Billion By 2030 | Driven By Latest Technol …
Risk Analytics Market by Offering (GRC Software, ERM Software, Third-party Risk Management Tools, Consulting Services, Risk Advisory Services), Risk Type (Operational Risks, Financial Risks, Technology Risks), and Verticals - Global Forecast to 2030.
The global risk analytics market [https://www.marketsandmarkets.com/Market-Reports/risk-analytics-market-210662258.html?utm_campaign=riskanalyticsmarket&utm_source=abnewswire.com&utm_medium=paidpr] is projected to expand at a compound annual growth rate (CAGR) of 9.7% between 2025 and 2030, rising from an estimated USD 32.25 billion to USD 51.34 billion. This growth is fueled…
Privileged Access Management Market Size Analysis, Growing Trends, Segmentations …
Privileged Access Management Market by Offering, Deployment Mode (On-Premises and Cloud), Vertical (BFSI, Government, IT & Ites, Healthcare, Telecommunications, Manufacturing, Energy & Utilities, Retail & Ecommerce) and Region - Global Forecast to 2028.
The global Privileged Access Management (PAM) market [https://www.marketsandmarkets.com/Market-Reports/privileged-access-management-market-113381799.html?utm_campaign=privilegedaccessmanagementmarket&utm_source=abnewswire.com&utm_medium=paidpr] is expected to expand from USD 2.9 billion in 2023 to USD 7.7 billion by 2028, registering a CAGR of 21.5% over the forecast period. This growth is driven by…
More Releases for Friedreich
Friedreich Ataxia Drug Market to Witness Growth Acceleration | Adverum Biotechno …
Friedreich Ataxia Drug Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report answers questions on the current and future technological advancements and development. It delivers an analysis of main manufactures and geographic regions.
The global Friedreich Ataxia Drug market is segmented by company, region (country), type, application, players, stakeholders, and others. The report includes the opportunities and encounters that are faced by…
Friedreich Ataxia Drug Market Emerging Trends || Leading Players are Edison Phar …
The market study on the global Friedreich Ataxia Drug Market will include the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2026, at the global level and across the major regions mentioned above.…
Friedreich Ataxia Global Key Players - Adverum Biotechnologies Inc, Biovista Inc …
Friedreich Ataxia
Overview
Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/3054160-friedreich-ataxia-pipeline-review-h1-2018
Major Key Players:
Adverum Biotechnologies Inc
Biovista Inc
Catabasis Pharmaceuticals Inc
Ixchel Pharma LLC
Pfizer Inc
Friedreich Ataxia Industry Major…
Friedreich Ataxia Key Players - Adverum Biotechnologies Inc, Biovista Inc, and C …
Friedreich Ataxia
Overview
Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/3054160-friedreich-ataxia-pipeline-review-h1-2018
Major Key Players:
Adverum Biotechnologies Inc
Biovista Inc
Catabasis Pharmaceuticals Inc
Ixchel Pharma LLC
Pfizer Inc
Friedreich Ataxia Industry Major…
Global Friedreich Ataxia Drug Market Research Report : Share, Growth, Revenue, T …
Market Research Hub (MRH) has recently added a new report to its vast online database. the global market for “Global friedreich ataxia drug market” research report 2017 has surfaced as one of the most promising markets in the pharmaceutical industry, thanks to the significant rise in research and development activities by leading vendors of Global friedreich ataxia drug market research report 2017 across the world.
Manufacturers have turned to technological…
Friedreich Ataxia - Pipeline Review, H2 2017 with Production, Consumption, Reven …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
